Market data not licensed for redistribution.

HLB

028300 · KOSDAQ · Medical Supplies and Other Pharmaceutical Products Manufacturing

– Previous close pending (official data.go.kr feed not active yet) Live price ↗

Source: Financial Services Commission stock price data (data.go.kr), updated once a day.

Daily price, 1 year

Key statistics

Market cap (KRW bn)–

PER–

PBR–

ROE %-53.7

Debt ratio % (liabilities / equity)115

Revenue TTM (KRW bn)97.5

Op. profit TTM (KRW bn)-98.1

Dividend yield %–

Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.

Upcoming risk events

Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.

2026-11-13

Bonds with warrants (BW): conversion / exercise period starts ↗

3.10% of shares · price ₩48,917 · refix floor ₩34,242 (70.0%) · size ₩199.8bn

Medium

See it in the full calendar →

Annual results (KRW bn)

	2021	2022	2023	2024	2025
Revenue	69.8	179.7	42.9	68.1	84.2
Operating profit	-101.0	-74.7	-125.0	-118.5	-104.2
Net income	-111.6	-98.6	-206.0	-108.0	-235.4

Quarterly results (KRW bn, 3 months)

	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	17.7	15.7	22.1	28.7	18.7	28.0
Operating profit	-28.8	-23.1	-23.0	-29.4	-23.2	-22.5
Net income	-68.9	-60.8	-76.4	-29.3	-40.9	-80.4

Largest shareholder

As of the 2025 annual report: 진양곤 and related parties hold 9.75% of common shares.

Recent disclosures

Date	Filing
2026-10-15	CB conversion / price adjustment 전환가액의조정	DART original
2026-10-12	IR event 기업설명회(IR)개최	DART original
2026-10-12	Clinical trial / regulatory approval 기타경영사항(자율공시) (HLB 간암 1차 치료제(리보세라닙,캄렐리주맙 병용요법) FDA에 재승인 서류 제출)	DART original
2026-09-08	CB conversion / price adjustment 전환사채(해외전환사채포함)발행후만기전사채취득	DART original
2026-09-07	Insider / major-holder ownership report 주식등의대량보유상황보고서(약식)	DART original
2026-08-28	CB conversion / price adjustment 전환가액의조정	DART original
2026-08-20	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-08-20	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-08-19	Securities registration / prospectus 증권발행결과(자율공시)	DART original
2026-08-14	Other 파생상품거래손실발생	DART original
2026-08-14	Periodic report (annual/half/quarterly) 반기보고서 (2026.06)	DART original
2026-08-05	Convertible bond issuance 주요사항보고서(전환사채권발행결정)	DART original

Past material filings and price reaction (market-adjusted)

Date	Filing type	On the news (vs. market)	Next day (vs. market)	20 days (vs. market)
2026-10-12	Clinical trial / regulatory approval	+4.9%	-2.5%	–
2026-08-05	Convertible bond issuance	+0.4%	+0.2%	-5.2%
2026-07-10	Clinical trial / regulatory approval	-31.5%	-3.8%	+2.9%
2026-04-07	Convertible bond issuance	-0.0%	+0.1%	-1.6%
2026-02-26	Revenue/profit change >=30% (15% large caps)	-0.5%	-0.1%	+7.2%
2026-01-26	Clinical trial / regulatory approval	+8.1%	-5.1%	-32.9%
2025-11-03	BW/EB issuance	+18.3%	-5.2%	-13.8%
2025-09-24	Convertible bond issuance	-0.9%	+3.2%	+19.1%
2025-08-20	Convertible bond issuance	+0.8%	+2.5%	-7.5%
2025-03-21	Clinical trial / regulatory approval	-29.9%	+0.8%	+22.5%

For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view